<?xml version="1.0" encoding="UTF-8"?>
<funding-group>
 <award-group id="award001">
  <funding-source>
   <institution-wrap>
    <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100008207</institution-id>
    <institution>AstraZeneca Canada</institution>
   </institution-wrap>
  </funding-source>
  <award-id>Unrestricted Grant</award-id>
  <principal-award-recipient>
   <name>
    <surname>Oâ€™Byrne</surname>
    <given-names>Paul M.</given-names>
   </name>
  </principal-award-recipient>
 </award-group>
 <funding-statement>The research reported in this article was funded by an unrestricted grant from AstraZeneca Canada to PMO. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
